# CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study

> **NCT00412412** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 34 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** CNF2024
- **DRUG:** CNF2024 + trastuzumab

## Key facts

- **NCT ID:** NCT00412412
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2012-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00412412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00412412, "CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00412412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*